This volume will comprehensively cover the multiplicity and diversity of mechanisms underlying resistance to the currently approved anti-cancer drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors, and their downstream pathways, playing driver or survival functions in cancer. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Format
Hardcover
Release
January 22, 2018
ISBN 13
9783319679303
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
This volume will comprehensively cover the multiplicity and diversity of mechanisms underlying resistance to the currently approved anti-cancer drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors, and their downstream pathways, playing driver or survival functions in cancer. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.